Table 1

Baseline demographic characteristics

Whole group
(n=208)
MACE
(n=42)
No MACE
(n=166)
P value
Age, years53±1455±1554±150.312
Male, n (%)139 (67%)32 (76%)107 (64%)0.149
Ethnicity
Caucasian, n (%)168 (81%)27 (64%)141 (85%)0.002
Non-Caucasian, n (%)40 (19%)15 (36%)25 (15%)0.002
Smoking history, n (%)73 (35%)13 (31%)60 (36%)0.529
BMI, kg/m229.0±5.628.6±5.629.2±5.60.545
Hypertension, n (%)76 (37%)16 (38%)60 (36%)0.815
Diabetes mellitus, n (%)31 (15%)4 (10%)27 (16%)0.273
Presenting symptoms
Palpitations, n (%)117 (56%)27 (64%)90 (54%)0.240
Chest pain, n (%)46 (22%)5 (11%)41 (25%)0.074
Syncope, n (%)40 (19%)12 (29%)28 (17%)0.086
Abnormal ECG, n (%)110 (53%)29 (69%)81 (49%)0.019
Steroid therapy at baseline, n (%)105 (51%)22 (52%)83 (50%)0.783
Beta-blocker at baseline, n (%)78 (38%)24 (57%)54 (33%)0.003
ACE-I or ARB at baseline, n (%)63 (30%)15 (36%)48 (29%)0.392
Pulmonary function tests
FEV1 %predicted82±23.985±27.623±23.10.567
FVC %predicted94±19.995±22.294±19.50.815
TLCo %predicted85±20.391±22.683±19.60.090
  • ACE-I, ace inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; FEV1, forced expiratory volume 1 second; FVC, forced vital capacity; MACE, major adverse cardiovascular event; TLCo, transfer factor for carbon monoxide.